David Altshuler, Vertex CSO
September 16, 2020 05:00 PM EDTUpdated September 17, 06:38 AM
Deals
Cell/Gene Tx

Mod­er­na picks up a $75M cash wind­fall as long­time col­lab­o­ra­tor Ver­tex signs up for a gene edit­ing as­sault on cys­tic fi­bro­sis

John Carroll

Editor & Founder

Af­ter nail­ing down the top drug fran­chise in cys­tic fi­bro­sis, Ver­tex $VRTX is turn­ing to the mR­NA afi­ciona­dos at Mod­er­na $MR­NA to use gene edit­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times